Слайд 2Противоопухолевая терапия:
химиотерапия
радиотерапия
вирусная онколитическая терапия
иммунотерапия
блокаторы чек-поинтов
![Противоопухолевая терапия: химиотерапия радиотерапия вирусная онколитическая терапия иммунотерапия блокаторы чек-поинтов](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/1099457/slide-1.jpg)
Слайд 3CTLA-4 - cytotoxic T-lymphocyte-associated protein 4
![CTLA-4 - cytotoxic T-lymphocyte-associated protein 4](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/1099457/slide-2.jpg)
Слайд 4PD-1 - Programmed cell death protein 1
![PD-1 - Programmed cell death protein 1](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/1099457/slide-3.jpg)
Слайд 6How is CTLA-4 controlled?
tyrosine-based motif GVYVKM
not phosphorylated → AP-2 binding →
![How is CTLA-4 controlled? tyrosine-based motif GVYVKM not phosphorylated → AP-2 binding](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/1099457/slide-5.jpg)
CTLA-4 is not on the surface
phosphorylated → no AP-2 binding → CTLA-4 on the surface → B7 binding
Слайд 8https://www.nature.com/articles/s41588-021-00778-2
![https://www.nature.com/articles/s41588-021-00778-2](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/1099457/slide-7.jpg)
Слайд 10https://www.nature.com/articles/s41571-019-0218-0
![https://www.nature.com/articles/s41571-019-0218-0](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/1099457/slide-9.jpg)